Axsome Therapeutics’ Dextromethorphan/Bupropion Blend Reduces Agitation in Alzheimer’s

By PacConAdmin | November 28, 2022

Axsome Therapeutics’ proprietary combination of dextromethorphan and bupropion — already approved for major depressive disorder as AXS-05 — also reduced the risk of agitation related to Alzheimer’s disease (AD), the company reported.
Source: Drug Industry Daily

Posted in Drug Industry Daily